Vertex Pharmaceuticals Incorporated $VRTX Stock Position Lowered by MGO One Seven LLC

MGO One Seven LLC cut its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 31.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,469 shares of the pharmaceutical company’s stock after selling 1,112 shares during the quarter. MGO One Seven LLC’s holdings in Vertex Pharmaceuticals were worth $1,291,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in Vertex Pharmaceuticals during the 2nd quarter worth $11,975,849,000. State Street Corp lifted its stake in shares of Vertex Pharmaceuticals by 1.2% in the 2nd quarter. State Street Corp now owns 11,871,459 shares of the pharmaceutical company’s stock worth $5,896,910,000 after acquiring an additional 141,320 shares during the period. Wellington Management Group LLP lifted its stake in shares of Vertex Pharmaceuticals by 1.1% in the 2nd quarter. Wellington Management Group LLP now owns 3,247,658 shares of the pharmaceutical company’s stock worth $1,613,209,000 after acquiring an additional 35,069 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Vertex Pharmaceuticals by 1.0% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,086,683 shares of the pharmaceutical company’s stock valued at $1,533,248,000 after acquiring an additional 29,287 shares in the last quarter. Finally, Bank of America Corp DE purchased a new stake in shares of Vertex Pharmaceuticals in the second quarter valued at about $1,509,651,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Down 1.2%

VRTX stock opened at $542.50 on Friday. The company’s 50 day simple moving average is $522.81 and its 200-day simple moving average is $481.42. The firm has a market capitalization of $137.69 billion, a PE ratio of 34.91, a P/E/G ratio of 2.84 and a beta of 0.28. Vertex Pharmaceuticals Incorporated has a 12 month low of $406.67 and a 12 month high of $568.67. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.34 and a quick ratio of 2.74.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 21.98%. The company had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same period in the previous year, the business earned $4.80 EPS. The firm’s revenue was up 11.8% on a year-over-year basis. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post 16.50 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on VRTX. Royal Bank Of Canada increased their price target on shares of Vertex Pharmaceuticals from $576.00 to $600.00 and gave the stock an “outperform” rating in a report on Tuesday. Stifel Nicolaus lifted their price objective on Vertex Pharmaceuticals from $500.00 to $563.00 and gave the company a “hold” rating in a report on Tuesday. UBS Group boosted their target price on Vertex Pharmaceuticals from $615.00 to $640.00 and gave the stock a “buy” rating in a research report on Tuesday. Weiss Ratings raised Vertex Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, October 16th. Finally, Evercore raised their price target on Vertex Pharmaceuticals from $535.00 to $600.00 and gave the company an “outperform” rating in a report on Wednesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $596.44.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported third-quarter revenue of $3.44 billion, up about 12% year over year, and raised its 2026 revenue forecast to $13.15 billion–$13.25 billion. Growth was supported by its cystic fibrosis business and newer products, including CASGEVY. The company also faces a key November 30 FDA decision date for povetacicept in IgA nephropathy. Q3 earnings call highlights
• Positive Sentiment: Multiple analysts raised Vertex price targets or reiterated Buy/Overweight ratings, including Barclays, TD Cowen, JPMorgan, Goldman Sachs, Stifel, Cantor Fitzgerald, RBC, UBS, Wells Fargo, and Scotiabank. The broad positive analyst tone points to confidence in the company’s outlook. Barclays price-target increase
• Positive Sentiment: A longer-term bullish view cited Vertex’s strong position in cystic fibrosis and its gradual expansion into other treatments as reasons it could remain an attractive biotech stock. Long-term outlook
• Neutral Sentiment: Third-quarter revenue exceeded analyst estimates, but earnings per share of $4.76 came in slightly below the $4.82 consensus—an offset to the encouraging sales and guidance update.
• Negative Sentiment: Morgan Stanley lowered its expectations for Vertex’s stock price, offering a counterpoint to the wave of target increases. Morgan Stanley outlook

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.